Literature DB >> 33841682

Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer.

Weiwei Gong1,2, Caixia Zhu1,3, Yueyang Liu1,4, Alexander Muckenhuber5, Holger Bronger1, Andreas Scorilas6, Marion Kiechle1, Julia Dorn1, Viktor Magdolen1, Tobias Dreyer1.   

Abstract

Triple-negative breast cancer (TNBC) patients have the worst outcome among all breast cancer subtypes. In oral squamous carcinoma cells, miR-378 was reported to target the mRNA of kallikrein-related peptidase 4 (KLK4), resulting in inhibition of cell proliferation, migration and invasion, induction of apoptosis, and reduction of tumor growth in vivo. Similarly, a miR-378/KLK4 axis has been proposed in prostate cancer. Here, we analyzed the correlation between miR-378 and KLK4 mRNA expression and determined the prognostic impact of both factors in TNBC. miR-378 and KLK4 mRNA expression levels were determined by quantitative PCR in tumor tissue of TNBC patients (n=103) and correlated with clinical parameters and patients' survival. There was no significant correlation between miR-378 and KLK4 mRNA expression. In univariate Cox regression analysis, elevated miR-378 expression was significantly associated with shortened disease-free survival (DFS, P=0.047) and overall survival (OS, P=0.031), high KLK4 mRNA levels were linked to a worse DFS (P=0.033). Combination of KLK4 mRNA and miR-378 (KLK4+miR-378, low/low versus high and/or high) allowed even better discrimination between favorable and unfavorable prognosis (DFS, P=0.008; OS, P=0.025). In multivariable analysis, miR-378 and KLK4+miR-378 expression remained independent predictive factors for DFS (P=0.014, P=0.010, respectively) and OS (P=0.016, P=0.049, respectively), while KLK4 mRNA only showed a trend towards significance for DFS (P=0.061). Our findings suggest that in TNBC there is no significant impact of miR-378 on KLK4 expression. Both factors, miR-378 and, to a lesser extent, KLK4 mRNA represent unfavorable prognostic markers in TNBC patients. AJTR
Copyright © 2021.

Entities:  

Keywords:  KLK4; Triple-negative breast cancer; clinical relevance; kallikrein-related peptidase; miR-378; prognostic marker

Year:  2021        PMID: 33841682      PMCID: PMC8014413     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  73 in total

Review 1.  Triple negative breast cancer: A thorough review of biomarkers.

Authors:  Jesse Lopes da Silva; Natalia Cristina Cardoso Nunes; Patricia Izetti; Guilherme Gomes de Mesquita; Andreia Cristina de Melo
Journal:  Crit Rev Oncol Hematol       Date:  2019-12-20       Impact factor: 6.312

2.  Association between mir-24 and mir-378 in formalin-fixed paraffin-embedded tissues of breast cancer.

Authors:  Jia-Yu Yin; Zhao-Qun Deng; Feng-Qiong Liu; Jun Qian; Jiang Lin; Qin Tang; Xiang-Mei Wen; Jing-Dong Zhou; Ying-Ying Zhang; Xiao-Wen Zhu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer.

Authors:  Lina Seiz; Matthias Kotzsch; Nicolai I Grebenchtchikov; Anneke J Geurts-Moespot; Susanne Fuessel; Peter Goettig; Apostolos Gkazepis; Manfred P Wirth; Manfred Schmitt; Arndt Lossnitzer; Fred C G J Sweep; Viktor Magdolen
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

4.  MicroRNA-378 regulates epithelial-mesenchymal transition and metastasis of melanoma by inhibiting FOXN3 expression through the Wnt/β-catenin pathway.

Authors:  Mengyao Sun; Xiaona Ma; Chen Tu; Xiaopeng Wang; Jianqiang Qu; Shuang Wang; Shengxiang Xiao
Journal:  Cell Biol Int       Date:  2019-07-23       Impact factor: 3.612

5.  Over-expression of miR-98 in FFPE tissues might serve as a valuable source for biomarker discovery in breast cancer patients.

Authors:  Zhao-Qun Deng; Jia-Yu Yin; Qin Tang; Feng-Qiong Liu; Jun Qian; Jiang Lin; Rui Shao; Ming Zhang; Li He
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

6.  Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer.

Authors:  Nancy Ahmed; Julia Dorn; Rudolf Napieralski; Enken Drecoll; Matthias Kotzsch; Peter Goettig; Eman Zein; Stefanie Avril; Marion Kiechle; Eleftherios P Diamandis; Manfred Schmitt; Viktor Magdolen
Journal:  Biol Chem       Date:  2016-12-01       Impact factor: 3.915

7.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.

Authors:  Michael D Mattie; Christopher C Benz; Jessica Bowers; Kelly Sensinger; Linda Wong; Gary K Scott; Vita Fedele; David Ginzinger; Robert Getts; Chris Haqq
Journal:  Mol Cancer       Date:  2006-06-19       Impact factor: 27.401

8.  Protease Activated Receptors 1 and 2 Correlate Differently with Breast Cancer Aggressiveness Depending on Tumor ER Status.

Authors:  Jon Lidfeldt; Pär-Ola Bendahl; Carina Forsare; Per Malmström; Mårten Fernö; Mattias Belting
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

9.  miR-378 functions as an onco-miRNA by targeting the ST7L/Wnt/β-catenin pathway in cervical cancer.

Authors:  Shengjie Li; Fengxia Yang; Meiyan Wang; Wenjun Cao; Zhen Yang
Journal:  Int J Mol Med       Date:  2017-08-30       Impact factor: 4.101

10.  MicroRNA-378 enhances migration and invasion in cervical cancer by directly targeting autophagy-related protein 12.

Authors:  Dongmei Tan; Chao Zhou; Sai Han; Xuetao Hou; Shufang Kang; Youzhong Zhang
Journal:  Mol Med Rep       Date:  2018-02-27       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.